IDT Australia Ltd, a pharmaceutical company, is navigating financial challenges with a negative price-to-earnings ratio, but remains a key player in the industry with a suite of services supporting research and development.

IDT Australia Ltd has halted acquisition talks with Myndbio due to delays, prompting a strategic reassessment amidst market fluctuations and financial challenges.